Abstract

Lung microinvasive adenocarcinoma (MIA) is a newly-defined subtype of early stage non-small cell lung cancer (NSCLC). However, its epidermal growth factor receptor (EGFR) mutation status and clinical significance remain unclear. The present study aimed to determine EGFR mutation characteristics and identify their significance in patients with resected lung MIA. The present study also analyzed clinicopathological differences between EGFR molecular subgroups defined as 19Del and L858R. The present study examined EGFR mutations in 79 consecutive lung MIA resection specimens and compared the differences in clinicopathological features between the EGFR wild-type and mutation groups, as well as between the 19Del and L858R subgroups. EGFR mutations were detected in 60 (75.95%) tumors. The most common mutations were 19Del (28 cases; 35.44%) and L858R (30 cases; 37.97%). Two patients harbored rare mutations and one of them had a concomitant double mutation. EGFR mutations were significantly associated with microinvasion component, thyroid transcription factor 1 (TTF-1) expression, intratumoral fibrosis and inflammatory cell infiltration. Subgroup evaluation indicated that there was a significant association between 19Del and tumor size, maximum diameter of microinvasion, presence of intratumoral fibrosis and inflammatory cell infiltration. Similar associations were observed for the L858R subgroup, and L858R was associated with TTF-1 expression. In particular, 19Del occurred more frequently in MIA with a smaller size, with a smaller microinvasive area, without TTF-1 expression, and lacking intratumoral fibrosis and inflammatory cell infiltration. By contrast, L858R was detected more frequently in MIA with entirely different tumor features. In conclusion, the results of the present study indicated that surgically resected MIA cases harboring different EGFR gene statuses exhibit distinct clinicopathological features. Significant differences in pathological features associated with the tumor microenvironment were identified in MIA with 19Del or L858R mutations. Therefore, the present study proposed that MIA should be classified into molecular subgroups based on EGFR mutation subtypes. The molecular sub-classification should be taken into account for prognostic evaluation and clinical management of MIA.

Highlights

  • Lung cancer is one of the most common types of cancer worldwide and it remains the leading cause of cancer‐associated mortality among all human malignancies [1]

  • The present study aimed to improve the understanding of the epidermal growth factor receptor (EGFR) mutation features, and their clinicopathological relevance, in microinvasive adenocarcinoma (MIA)

  • The results indicated that lung MIA occurred more frequently in females, patients who had never smoked, patients aged 51‐60 years and patients with a single tumor in the right lung

Read more

Summary

Introduction

Lung cancer is one of the most common types of cancer worldwide and it remains the leading cause of cancer‐associated mortality among all human malignancies [1]. The treatment strategy for NSCLC has changed significantly and the therapeutic efficacy has improved with the application of novel individualized therapy. This is based on specific molecular alterations that define biological characteristics of lung cancer and may be used to predict treatment response [4]. EGFR tyrosine kinase inhibitors (TKIs) have exhibited promising clinical efficacy for the treatment of advanced NSCLC harboring sensitive EGFR mutations [8]. Phase III randomized trials have provided robust evidence that EGFR TKIs could be applied as first‐line therapy for advanced NSCLC with particular EGFR mutations [9,10,11,12]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.